Hypoxen: complement-pathway inhibition lead — RU2205002C1
Б.Б. Шойбонов, А.Н. Онтобоев, А.А. Зинченко, В.А. Алёшкин · 2003 · RU2205002C1 · patent family 20255843
Published 2003-05-27.
Reported patent results
Narrative findings; numerical extraction incomplete
The experiments support a complement-interaction hypothesis rather than established clinical immune control.
Hypoxen in-vitro complement-binding and hemolytic-system experiments; no autoimmune patient treatment trial.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| C1q-related activity | Concentration-dependent inhibition of C1q-associated activity reported | Laboratory complement system, not autoimmune disease activity |
| Affinity-value ambiguity | The indexed text has an unclear exponent in the stated affinity value; no corrected binding constant is entered | An OCR/exponent problem can change the value by many orders of magnitude |
A biochemical inhibition result does not prove selective immune tolerance, clinical autoimmune efficacy or therapeutic safety.
Source for the extracted data ↗ · Checked 2026-11-06
Patent claims and provenance
Use. This use patent proposes Hypoxen in relation to C1q/C1 complement inhibition.
A mechanistic patent lead is not evidence of clinical autoimmune disease control or selective immune tolerance.
- Publication
- RU2205002C1 ↗ · 2003-05-27
- Earliest priority / filing
- 2002-07-11 / 2002-07-11
- Original applicant / assignee
- Государственное учреждение "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н.Габричевского"
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 20255843 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Hypoxen as inhibitor of c1q subcomponent and c1 component of human complement system
Inventors: Б.Б. Шойбонов; А.Н. Онтобоев; А.А. Зинченко; В.А. Алёшкин.
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- A mechanistic patent lead is not evidence of clinical autoimmune disease control or selective immune tolerance.
- A biochemical inhibition result does not prove selective immune tolerance, clinical autoimmune efficacy or therapeutic safety.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; the record gives its source-check date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Original patent text and indexed metadata
Review depth: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Related-report group: patent-family-20255843. Reports in this group are not assumed to be independent trials.
Source access and review scope
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Recorded source-check date: 2026-11-06. This date does not imply a completed systematic review.
Source type: Patent publication
Citation and original source
Original source: Б.Б. Шойбонов, А.Н. Онтобоев, А.А. Зинченко, В.А. Алёшкин. Hypoxen: complement-pathway inhibition lead — RU2205002C1 RU2205002C1 · patent family 20255843 2003.
Molekul research summary: https://molekul.io/research/patent-ru2205002c1. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry